

LA JOLLA PHARMACEUTICAL CO  
Form 8-K  
October 26, 2005

---

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported):

October 25, 2005

La Jolla Pharmaceutical Company

(Exact name of registrant as specified in its charter)

Delaware

0-24274

33-0361285

(State or other jurisdiction  
of incorporation)

(Commission  
File Number)

(I.R.S. Employer  
Identification No.)

6455 Nancy Ridge Drive, San Diego,  
California

92121

(Address of principal executive offices)

(Zip Code)

Registrant's telephone number, including area code:

(858) 452-6600

Not Applicable

Former name or former address, if changed since last report

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))



**Top of the Form**

**Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.**

On October 25, 2005, La Jolla Pharmaceutical Company (the "Company") received a letter from the Nasdaq Listing Qualifications Department indicating that the Company is not in compliance with the minimum \$1.00 bid price requirement for continued listing pursuant to Nasdaq Marketplace Rule 4450(a)(5) and is subject to delisting.

The Company intends to make a timely request for a hearing before a Nasdaq Listing Qualifications Panel (the "Panel"). This request for a hearing will automatically stay the delisting of the Company's common stock pending the Panel's review and determination. However, the Company can give no assurances that the Panel will grant its request for continued listing. Until the Panel's final determination and the expiration of any exception granted by the Panel, the Company's common stock will continue to be traded on the Nasdaq Stock Market.

The press release announcing the Company's receipt of the notice is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits

The following exhibit is filed with this Current Report on Form 8-K:

| Exhibit No. | Description                           |
|-------------|---------------------------------------|
| 99.1        | Press Release, dated October 26, 2005 |

**Top of the Form**

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

La Jolla Pharmaceutical Company

*October 26, 2005*

By: */s/ Gail A. Sloan*

---

*Name: Gail A. Sloan*

*Title: Vice President of Finance and Secretary*

---

**Top of the Form**

Exhibit Index

| <b><u>Exhibit No.</u></b> | <b><u>Description</u></b>             |
|---------------------------|---------------------------------------|
| 99.1                      | Press Release, dated October 26, 2005 |